Comparative Pharmacology
Head-to-head clinical analysis: ALEVE versus NALFON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE versus NALFON.
ALEVE vs NALFON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Fenoprofen, a propionic acid derivative, nonselectively inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
NALFON (fenoprofen) 200-600 mg orally 3-4 times daily; maximum dose 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
3-4 hours (terminal half-life in healthy adults; prolonged in elderly and hepatic impairment).
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Renal: 90% (mostly as glucuronide conjugates and unchanged drug; unchanged drug ~1-5%); Fecal: <5%; Biliary: negligible.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)